Strug­gling CTI gets a mixed bag of PhI­II re­sults for a lead drug still un­der a full hold at the FDA

With its stock firm­ly plant­ed in pen­ny ter­ri­to­ry, the strug­gling CTI Bio­Phar­ma $CTIC re­vealed that its top as­set pa­cri­tinib achieved mixed re­sults in a Phase III study, hit­ting one end­point and miss­ing an­oth­er ac­cord­ing to pre­lim­i­nary num­bers. The drug, though, was put on a full clin­i­cal hold back in Feb­ru­ary, af­ter the FDA took a look at new da­ta in­di­cat­ing that pa­tients in the drug arm were dy­ing faster than sub­jects in the con­trol arm.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER